Compare SKYW & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SKYW | GPCR |
|---|---|---|
| Founded | 1972 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.4B |
| IPO Year | 1994 | 2023 |
| Metric | SKYW | GPCR |
|---|---|---|
| Price | $111.38 | $48.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $123.67 | $103.17 |
| AVG Volume (30 Days) | 440.5K | ★ 531.6K |
| Earning Date | 04-23-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.20 | N/A |
| EPS | ★ 5.04 | N/A |
| Revenue | ★ $2,971,963,000.00 | N/A |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $3.55 | N/A |
| P/E Ratio | $21.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $77.89 | $15.80 |
| 52 Week High | $123.94 | $94.90 |
| Indicator | SKYW | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 65.01 | 47.79 |
| Support Level | $95.93 | $43.76 |
| Resistance Level | N/A | $57.15 |
| Average True Range (ATR) | 3.86 | 2.67 |
| MACD | 0.77 | -0.49 |
| Stochastic Oscillator | 84.44 | 40.83 |
SkyWest Inc offers commercial air services in the United States, Canada, Mexico, and the Caribbean. Additionally, it leases aircraft to capable users to help generate revenue. SkyWest generally provides regional flights and utilizes smaller, lower-cost aircraft to carry passengers who book tickets through partner airlines. It partners with carriers to fly and operate aircraft for a fee and may use the carriers' brands and ground support to coordinate marketing and transport passengers. The company has two reportable segments: SkyWest Airlines and SWC, which generate maximum revenue, and SkyWest Leasing activities.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.